Scienture Holdings, Inc. (NASDAQ: SCNX) announced entering into a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at $1.20 per share in a registered direct offering.
The gross proceeds for the offering are expected to be around $3.9 million before expenses.
Offering Details
3,225,000 shares of common stock at $1.20 per share in a registered direct offering.
Gross Proceeds
The offering is expected to generate approximately $3.9 million before deducting expenses.
Closing Date
The offering is set to close on August 15, 2025, subject to customary closing conditions.
- Maxim Group LLC is the sole placement agent for the offering.
- The offering is made through an effective shelf registration statement on Form S-3 filed with the SEC.
- Investors can obtain the prospectus supplement and accompanying documents from Maxim Group LLC or the SEC's website.
This registered direct offering signifies a strategic move by Scienture Holdings to raise funds for future endeavors in the pharmaceutical industry, showcasing investor confidence in the company's growth prospects.